Cite
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa .
MLA
Contreras-Gómez, María José, et al. “Role of the Multi-Drug Efflux Systems on the Baseline Susceptibility to Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Clinical Isolates of Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas Aeruginosa .” Frontiers in Pharmacology, vol. 13, Oct. 2022, p. 1007162. EBSCOhost, https://doi.org/10.3389/fphar.2022.1007162.
APA
Contreras-Gómez, M. J., Martinez, J. R. W., Rivas, L., Riquelme-Neira, R., Ugalde, J. A., Wozniak, A., García, P., Munita, J. M., Olivares-Pacheco, J., & Alcalde-Rico, M. (2022). Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa . Frontiers in Pharmacology, 13, 1007162. https://doi.org/10.3389/fphar.2022.1007162
Chicago
Contreras-Gómez, María José, José R W Martinez, Lina Rivas, Roberto Riquelme-Neira, Juan A Ugalde, Aniela Wozniak, Patricia García, José M Munita, Jorge Olivares-Pacheco, and Manuel Alcalde-Rico. 2022. “Role of the Multi-Drug Efflux Systems on the Baseline Susceptibility to Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Clinical Isolates of Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas Aeruginosa .” Frontiers in Pharmacology 13 (October): 1007162. doi:10.3389/fphar.2022.1007162.